- Home
- CR vs EXEL Comparison
CR vs EXEL Comparison
Compare CR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CR
- EXEL
- Stock Information
- Founded
- CR 1855
- EXEL 1994
- Country
- CR United States
- EXEL United States
- Employees
- CR N/A
- EXEL N/A
- Industry
- CR Metal Fabrications
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CR Industrials
- EXEL Health Care
- Exchange
- CR Nasdaq
- EXEL Nasdaq
- Market Cap
- CR 9.4B
- EXEL 9.4B
- IPO Year
- CR N/A
- EXEL 2000
- Fundamental
- Price
- CR $165.10
- EXEL $36.85
- Analyst Decision
- CR Strong Buy
- EXEL Buy
- Analyst Count
- CR 6
- EXEL 18
- Target Price
- CR $174.80
- EXEL $37.24
- AVG Volume (30 Days)
- CR 302.1K
- EXEL 2.6M
- Earning Date
- CR 01-27-2025
- EXEL 02-11-2025
- Dividend Yield
- CR 0.56%
- EXEL N/A
- EPS Growth
- CR 13.69
- EXEL 170.77
- EPS
- CR 5.05
- EXEL 1.76
- Revenue
- CR $2,131,199,999.00
- EXEL $2,168,701,000.00
- Revenue This Year
- CR $9.28
- EXEL $5.36
- Revenue Next Year
- CR $6.57
- EXEL $10.59
- P/E Ratio
- CR $35.88
- EXEL $20.94
- Revenue Growth
- CR 2.15
- EXEL 18.49
- 52 Week Low
- CR $121.07
- EXEL $20.14
- 52 Week High
- CR $188.52
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- CR 45.76
- EXEL 65.59
- Support Level
- CR $167.88
- EXEL $34.01
- Resistance Level
- CR $173.67
- EXEL $35.46
- Average True Range (ATR)
- CR 3.76
- EXEL 1.09
- MACD
- CR -0.65
- EXEL 0.36
- Stochastic Oscillator
- CR 5.33
- EXEL 95.70
About CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into three segments: aerospace and electronics, process flow technologies, and engineered materials. Crane generated approximately $2.1 billion in revenue in 2023.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.